Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic-Myeloproliferative Diseases”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01445080
What this trial is testing

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Who this might be right for
Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT00674479
What this trial is testing

INCB018424 in Patients With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaMyelodysplastic Syndrome+1 more
M.D. Anderson Cancer Center 51
Early research (Phase 1)Study completedNCT00101296
What this trial is testing

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)+16 more
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT00049634
What this trial is testing

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+1 more
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01824693
What this trial is testing

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Who this might be right for
Juvenile Myelomonocytic Leukemia
Children's Oncology Group 30
Testing effectiveness (Phase 2)Study completedNCT00003675
What this trial is testing

Topotecan in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Alliance for Clinical Trials in Oncology 100
Testing effectiveness (Phase 2)Looking for participantsNCT03589729
What this trial is testing

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Who this might be right for
Acute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated Cells+4 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT00006350
What this trial is testing

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Early research (Phase 1)Study completedNCT04167917
What this trial is testing

NTX-301 in MDS/AML

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
University of Alabama at Birmingham 22
Not applicableStudy completedNCT00014235
What this trial is testing

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+74 more
Fred Hutchinson Cancer Center 160
Testing effectiveness (Phase 2)Study completedNCT02728050
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid Leukemiade Novo Myelodysplastic Syndrome+2 more
University of Washington 84
Testing effectiveness (Phase 2)Ended earlyNCT00113321
What this trial is testing

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT04487106
What this trial is testing

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01839916
What this trial is testing

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+61 more
University of Chicago 77
Testing effectiveness (Phase 2)Study completedNCT01235572
What this trial is testing

Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy

Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)+14 more
Fred Hutchinson Cancer Center 200
Testing effectiveness (Phase 2)Study completedNCT00423514
What this trial is testing

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT00357084
What this trial is testing

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Who this might be right for
Cancer
Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)WithdrawnNCT01652014
What this trial is testing

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+51 more
University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Ended earlyNCT00589316
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+7 more
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)UnknownNCT00043134
What this trial is testing

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 220
Next Page
26